Abstract
The rapidly growing interest in kinases as drug targets has prompted the development of many kinase assay technologies. These technologies can be grouped into three categories: radiometric assays, phospho-antibody-dependent fluorescence/luminescence assays, and phospho-antibody-independent fluorescence/luminescence assays. This article will review some of the major kinase assay technologies on the market, with particular emphasis on the newest systems. We will describe the physical principles, the practical advantages and drawbacks, and the potential applications of these technologies in kinase drug discovery. Most of these technologies are suitable for HTS, but only a few can be utilized for kinetic and mechanistic studies. Significant progress towards development of generic assays, free of radioisotopes and custom reagents such as phospho-specific antibodies, has been made in recent years. However, due to various limitations of each format, none of these generic assay technologies can yet claim to be truly universal. Several factors, including the intended applications, cost, timeline, expertise, familiarity, and comfort level, should be considered prior to pursuing a particular kinase assay technology.
Keywords: Kinase, assay, phospho-antibody, radiometric
Current Drug Discovery Technologies
Title: Current In Vitro Kinase Assay Technologies: The Quest for a Universal Format
Volume: 5 Issue: 1
Author(s): Yong Jia, Christopher M. Quinn, Silvia Kwak and Robert V. Talanian
Affiliation:
Keywords: Kinase, assay, phospho-antibody, radiometric
Abstract: The rapidly growing interest in kinases as drug targets has prompted the development of many kinase assay technologies. These technologies can be grouped into three categories: radiometric assays, phospho-antibody-dependent fluorescence/luminescence assays, and phospho-antibody-independent fluorescence/luminescence assays. This article will review some of the major kinase assay technologies on the market, with particular emphasis on the newest systems. We will describe the physical principles, the practical advantages and drawbacks, and the potential applications of these technologies in kinase drug discovery. Most of these technologies are suitable for HTS, but only a few can be utilized for kinetic and mechanistic studies. Significant progress towards development of generic assays, free of radioisotopes and custom reagents such as phospho-specific antibodies, has been made in recent years. However, due to various limitations of each format, none of these generic assay technologies can yet claim to be truly universal. Several factors, including the intended applications, cost, timeline, expertise, familiarity, and comfort level, should be considered prior to pursuing a particular kinase assay technology.
Export Options
About this article
Cite this article as:
Jia Yong, Quinn M. Christopher, Kwak Silvia and Talanian V. Robert, Current In Vitro Kinase Assay Technologies: The Quest for a Universal Format, Current Drug Discovery Technologies 2008; 5 (1) . https://dx.doi.org/10.2174/157016308783769414
DOI https://dx.doi.org/10.2174/157016308783769414 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Conceptual Framework of Comorbidity for Investigation in the Context of Psychiatric Disturbance
Current Psychiatry Reviews Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery Fontan Circulation Might be Associated with Peripartum Cardiomyopathy: A Review of Mechanistic and Clinical Aspects
Current Cardiology Reviews Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
Current Vascular Pharmacology Editorial (Hot Topic: Metabolic Syndrome and Cardiovascular Health: A Look Beyond the Horizon)
Current Pharmaceutical Design Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
Current Neuropharmacology Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress
Current Cardiology Reviews Lysosomal Molecules are Up-Regulated in the Articular Cartilage Explants Subjected to Oxidative Stress and in the Cartilage from an Osteoarthritis-Induced Rat Model
Recent Patents on Biomarkers Extrahepatic Metabolism may Complicate the IVIVC in Rats
Drug Metabolism Letters The Zebrafish as a Novel Tool for Cardiovascular Drug Discovery
Recent Patents on Cardiovascular Drug Discovery Prevention of Cell Damage in Ischaemic-Reperfusion: Mitochondrial Respiratory Chain as a Pharmacological Target
Letters in Drug Design & Discovery Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery